ReviewMelanoma management2026
Insurance, race, and socioeconomic disparities in systemic therapy receipt for melanoma in the United States: a systematic review.
Review in Melanoma management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough evidence suggests disparities in melanoma treatment, no comprehensive summary exists on whether insurance type, race/ethnicity, or socioeconomic status consistently influence systemic therapy receipt. Understanding these associations may inform strategies to reduce inequities.
methodsWe conducted a systematic review of United States (US) based studies assessing systemic therapy receipt by insurance, socioeconomic status, and race/ethnicity. Searches of PubMed, Embase, and Web of Science were performed through July 10, 2025. Evidence quality was evaluated using the Oxford Center for Evidence-Based Medicine.
resultsOf 6,604 records screened and 223 full-texts reviewed, 30 retrospective cohort studies were included, encompassing 1,212,437 melanoma patients (1975-2021). Twenty-five studies stratified by insurance, 24 by socioeconomic status, and 21 by race/ethnicity. Insurance-based disparities were reported in 88% of studies, socioeconomic status-based disparities were reported in 75% of studies, and race/ethnicity- based disparities were reported in 38% of studies. Although 67% of studies used the National Cancer Database, findings were inconsistent across studies.
conclusionInsurance and socioeconomic status may be more consistent drivers of disparities in systemic therapy receipt for melanoma than race/ethnicity. However, variability in identifying disparities, even among studies using the same database, may complicate targeted interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.